RANKINGS

POPULAR STOCKS

Oneness Biotech Co., Ltd.

Taipei Exchange:4743.TWO

Location

Taiwan

Market Cap

USD 1.24 B

Share Price

USD 2.59

Avg Daily Volume

2,132,457

Change (1 day)

10.10%

Change (1 year)

-40.63%

Change (YTD)

-2.45%

Oneness Biotech Co., Ltd. Inventory for the year ending December 31, 2024: USD 3.57 M

Oneness Biotech Co., Ltd. Inventory is USD 3.57 M for the year ending December 31, 2024, a -11.29% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.
  • Oneness Biotech Co., Ltd. Inventory for the year ending December 31, 2023 was USD 4.02 M, a 8.09% change year over year.
  • Oneness Biotech Co., Ltd. Inventory for the year ending December 31, 2022 was USD 3.72 M, a 5.62% change year over year.
  • Oneness Biotech Co., Ltd. Inventory for the year ending December 31, 2021 was USD 3.52 M, a 73.33% change year over year.
  • Oneness Biotech Co., Ltd. Inventory for the year ending December 31, 2020 was USD 2.03 M, a 25.71% change year over year.
Key data
Date Inventory Current Assets Property, Plant, Equipment (Net) Total Assets
Market news
Taipei Exchange: 4743.TWO

Oneness Biotech Co., Ltd.

CEO Mr. Nien-Yi Chen
IPO Date Sept. 23, 2011
Location Taiwan
Headquarters No.236, Xinyi Road
Employees 180
Sector 🏥 Health Care
Industries
Clinical Trials
🧬 Biotechnology
💊 Pharmaceuticals
Description

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.

Similar companies

6547.TWO

Medigen Vaccine Biologics Corporation

USD 1.58

-2.24%

4174.TWO

OBI Pharma, Inc.

USD 1.16

-1.69%

4128.TWO

Microbio Co., Ltd.

USD 0.97

3.25%

StockViz Staff

June 17, 2025

Any question? Send us an email